UNC School of Medicine: Ledger

Stories naming UNC School of Medicine. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Investor	Rounds	Invested
No investors recorded yet. Know one?

Company	Kind	Announced	Price	Sources
UNC School of Medicine is not recorded as having acquired anything.

Name	Role	Sources
John Buse	Chief, Division of Endocrinology and Director of Diabetes	Brandon BioCatalyst portfolio

News

Glyscend Therapeutics Releases New Phase 1 Biomarker Results and Initiates Phase 2 Clinical Trial under an IND for GLY-200 as a Potential First-in-Class Type 2 Diabetes Treatment

Glyscend reports encouraging Phase 1 biomarker data for its diabetes drug GLY-200, announces US FDA clearance of its investigational new drug application, and has begun enrolling patients in a Phase 2 trial.

Brandon BioCatalyst portfolio 21 Sep 2022 Adelaide Medical School Glyscend Johns Hopkins University Royal Adelaide Hospital UNC School of Medicine Ashish Nimgaonkar Professor Christopher Rayner John Buse

UNC School of Medicine

Funding history

Investors

What UNC School of Medicine bought

People

Coverage

Glyscend Therapeutics Releases New Phase 1 Biomarker Results and Initiates Phase 2 Clinical Trial under an IND for GLY-200 as a Potential First-in-Class Type 2 Diabetes Treatment